Zhejiang Yihan Pharmaceutical

Zhejiang Yihan Pharmaceutical is a clinical-stage biopharmaceutical company based in China, specializing in the development of innovative small molecule therapies for metabolic diseases. The company's primary focus is on the discovery and development of multi-target agonists, particularly those targeting the GLP-1, GIP, and glucagon receptors to treat conditions such as type 2 diabetes and obesity. Their lead programs aim to provide oral alternatives to injectable incretin therapies, leveraging advanced medicinal chemistry to optimize metabolic outcomes. Zhejiang Yihan Pharmaceutical operates within the high-growth metabolic health sector, positioning itself as a competitive player in the next generation of weight loss and diabetes management treatments.